Pazopanib (Pazopanib) belongs to which generation of targeted drugs and introduction to its clinical advantages

Pazopanib (trade name Votrient) is an oral small molecule multi-target tyrosine kinase inhibitor mainly used to treat advanced clear cell renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). According to the development history of targeted drugs, pazopanib belongs to the second generation of multi-target targeted drugs. Compared with the first-generation single-target inhibitors, the second-generation drugs can act on multiple signaling pathways simultaneously, improve treatment coverage, overcome some resistance mechanisms, and thus demonstrate broader anti-tumor potential in clinical applications.

Pazopanib mainly targets vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), blood Small plate-derived growth factor receptor (PDGFRα, PDGFRβ), stem cell factor receptor (c-KIT) and other tyrosine kinases. By simultaneously inhibiting angiogenesis and tumor cell proliferation signals, pazopanib can reduce tumor blood supply, inhibit tumor growth, and delay the metastasis process. This multi-target inhibition strategy allows pazopanib to show certain advantages in monotherapy or combination therapy.

In clinical trials, pazopanib demonstrated significant anti-tumor efficacy. For patients with advanced clear cell renal cell carcinoma, pazopanib can significantly prolong progression-free survival (PFS), and some patients can achieve long-term disease control. Compared with other targeted drugs such as sorafenib, pazopanib is better tolerated, has relatively mild gastrointestinal and skin adverse reactions, and has higher patient compliance. At the same time, its oral administration method facilitates long-term use by patients and improves their quality of life.

As a second-generation multi-target drug, pazopanib plays an important role in the treatment of advanced solid tumors. Its multi-pathway inhibition mechanism can not only be used for clear cell renal cell carcinoma and soft tissue sarcoma, but also provides a basis for future exploration of combined immunotherapy and overcoming drug resistance mechanisms. As clinical experience and research data continue to accumulate, pazopanib is expected to play greater value in precision medicine and personalized treatment, providing effective treatment options for more patients.

Reference link:https://www.drugs.com